case review: t-dm1 for residual her2 breast cancer
Published 5 years ago • 615 plays • Length 5:15Download video MP4
Download video MP3
Similar videos
-
7:11
case 1: adjuvant therapy for residual disease in her2 breast cancer
-
0:56
t-dm1 as part of our standard of care with residual her 2 disease
-
3:51
adjuvant t-dm1 therapy for early-stage her2 breast cancer
-
6:40
her2 breast cancer: managing patients on t-dm1
-
2:02
katherine trial: t-dm1 cuts her2-positve invasive breast cancer recurrence
-
1:36
phase 3 trial investigates t-dm1 and pertuzumab in her2 breast cancer
-
1:55
benefit of antibody drug conjugate t-dm1 in her2 bc
-
3:48
neoadjuvant t-dm1 in early-stage her2 breast cancer
-
3:21
how breast cancer treatment kadcyla (t-dm1) works
-
1:11
neratinib/t-dm1 doses recommended for phase ii trial in breast cancer
-
4:39
case 1: approach to early stage, her2 breast cancer
-
5:33
case 1: guidelines for her2 testing in breast cancer
-
7:45
trastuzumab emtansine in her2 breast cancer
-
1:14
dr. perez discusses t-dm1 and the marianne trial
-
4:18
case 1: early-stage her2 breast cancer
-
0:59
sequencing her2-targeted therapies in breast cancer
-
2:07
dr waks on ongoing research in residual her2 breast cancer
-
1:07
dr. tripathy discusses impact of t-dm1 in her2 breast cancer
-
1:00
aphinity update - pertuzumab in her2 breast cancer